Abstract: A grip member has a grip proper (1) made of a shape-memory resin in the shape of a bar, a connecting pin (4) disposed in one terminal part of the grip proper, a forked part (3) formed integrally in the other terminal side of the grip proper, and an annular part (2) formed integrally slightly toward one end of the grip proper (1) and adapted for enabling the forked part (3) to twine thereon. The grip member is enabled to cope easily with a delicate change in the gripping condition by heating the grip proper (1) and the vicinity thereof to a temperature surpassing the glass transition point of the shape-memory resin thereby endowing the shape-memory rubber with a rubbery state, causing the forked part (3) to twine itself around the annular part (2) in such a manner as to impart the shape of a loop to the grip proper.

Abstract: A sifter frame is composed of a pair of frame elements including an outer frame and an inner frame, and the outer frame is formed from a frame member having the same height and includes a pair of fine powder dropping ports, a rough powder dropping port and a rectangular fine powder receiving plate disposed in a region surrounded by these openings and one of the outer block frame members and the inner frame is fitted with the space above the receiving plate.

Abstract: A sifter frame is composed of a pair of frame elements including an outer frame and an inner frame, and the outer frame is formed from a frame member having the same height and includes a pair of fine powder dropping ports, a rough powder dropping port and a rectangular fine powder receiving plate disposed in a region surrounded by these openings and one of the outer block frame members and the inner frame is fitted with the space above the receiving plate.

Abstract: A pharmaceutical composition for treating viral diseases, such as pasta, gargle, gel, ointment, suppository, spray, etc., containing interferon in a stable state which comprises an effective amount of human interferon, 15 to 60% by weight of a tri or higher polyhydric sugar alcohol and an organic acid buffer as stabilizers, and a conventional pharmaceutical carrier or diluent. The pH of the composition is about 3 to 6. Optionally, the composition can further contain as a stabilizer an anionic surfactant and/or albumin.

Abstract: A pharmaceutical composition for treating erythematodes, particularly, lupus erythematodes discoides, or mycosis, particularly, candidasis, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from erythematodes and mycosis by using this composition is also provided.

Abstract: A pharmaceutical composition for treating keratosic disorders of skin and mucosa, particularly, lichen planus and leukoplakia, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from keratosic disorders of skin and mucosa by using this composition is also provided.